 |
Anti-Infectives
All of MOLOGEN’s platform technologies are fundamentally suited for use as prophylactics against or as a cure for infectious diseases. MOLOGEN’s primary focus here is the application of its highly promising MIDGE-Th1 technology. With this vector in particular, specific cellular and humoral immune responses to viruses, bacteria or parasites can be generated. Previous experiments have shown that through the use of MIDGE-Th1 vectors the amount of vaccine to be administered can be reduced and the quality of the immune reaction can be improved.
The most advanced area here is the development of vaccines and therapeutic agents against leishmaniasis, a serious parasitic disease.
In addition, more extensive studies on the treatment of feline leukemia virus (FeLV, also known as cat leukemia) are currently ongoing.
MOLOGEN®, MIDGE® and dSLIM® are registered trademarks of MOLOGEN AG |
|
